参考文献/References:
[1] Kwekkeboom D,Krenning EP,de Jong M.Peptide receptor imaging and therapy.J Nucl Med,2000,41(10):1704-1713.
[2] Papotti M,Croce S,Bello M,et al.Expression of somatostatin receptor types 2,3 and 5 in biopsies and surgical specimens of human lung turnouts.Correlation with preoperative octreotide scintigraphy.Virchows Arch,2001,439(6):787-797.
[3] Rablnowitz I,Telepak R,Lee FC.Octreotide scans are positive in a subset of patients with hepatocellular carcinoma.Clin Nucl Med,2002,27(7):499-502.
[4] Reubi JC.Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.Neuroendocrinology,2004,80 Suppl 1:51-56.
[5] Oberg K,Eriksson B.Nuclear medicine in the detection,staging and treatment of gastrointestinal earcinoid tumours.Best Pract Res Clin Endocrinol Metab,2005,19(2):265-276.
[6] Gotthardt M,Behe MP,Alfke H,et al.Imaging lung tumors with peptide-based radioligands.Clin Lung Cancer,2003,5(2):119-124.
[7] Hofland LJ,Lamberts SW,van Hagen PM,et al.Crucial role for somatostatin receptor subtype 2 in determining the uptake of[IIIIn-DTPA-D-Phel]octreotide in somatostatin receptor-positive organs.]Nucl Med,2003,44(8):1315-1321.
[8] Bauer W,Briner U,Doepfner W,et al.SMS 201-995:a very potent and selective octapeptide analogue of somatostatin with prolonged action.Life Sci,1982,31(11):1133-1140.
[9] 王丽华,汪勇先,尹端沚.生长抑素及其类似物的标记技术的发展.核技术,2003,26(7):537-544.
[10] 徐文贵,马庆杰,张建中,等.肿瘤特异性受体显像剂Octreotide (奥曲肽)的99Tcm标记与纯化方法研究.中国老年学杂志,2004,24(12):1133-1134.
[11] 武凤玉,左书耀.放射性核素标记奥曲肽肿瘤受体显像研究进展.国外医学:肿瘤学分册,2005,32(10):760-763.
[12] 武鸿文,华西医科.肿瘤生长抑素受体显像剂99Tcm-octreotide的制备及鉴定.中华核医学杂志,2000,20(3):112-116.
[13] 武鸿文,管昌田,梁正路.99Tcm直接法标记Octreotide.同位素,2000,13(3):152-156.
[14] 王叙馥,左书耀,邵文博,等.肿瘤受体显像剂99Tcm-octreotide的放化纯度分析.同位素,2003,16(1):26-29.
[15] 章斌.188Re直接标记octreotide的方法学.国外医学:放射医学核医学分册,2002,26(5):220-222.
[16] Thakur ML,Kolan HR,Rifat S,et al.Vapreotide label with 9c for imaging tumor.Int J Oncol,1996,6:445-451.
[17] 马庆杰,徐文贵,张建中,等.SnCl2还原法生长抑素受体显像剂99Tcm-octreotide (奥曲肽)的生物活性研究.中国老年学杂志,2004,24(11):1048-1049.
[18] 景红丽,李方,杜延荣,等.99mTc-HYNIC-TOC生长抑素受体显像诊断胰腺神经内分泌肿瘤的临床应用.胃肠病学,2008,13(4):195-199.
[19] 王胜军,汪静,邓敬兰,等99Tcm-HYNIC-Octreotide的标记及其在脑膜瘤诊断中的初步应用.中国临床医学影像杂志,2008,19(8):551-554.
[20] 邓念英,张金山,冼有卿.99mTc-奥曲肽和99mTc-MIBI显像在乳腺癌临床的应用价值.中国普外基础与临床杂志,2004,11(1):17-19.
[21] 段炼,李险峰,陆克义,等.99Tcm-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用.中华眼科杂志,2006(12).5
[22] 武鸿文,管昌田.99mTc-octreotide的动物体内分布,药物动力学和临床初步应用研究.华西医科大学学报,2000,31(4):481-484.
[23] 王佳琼,王自正,姚薇萱,等.99mTc-MIBI与99mTc-Octreotide生长抑素受体显像诊断乳腺癌的对比研究.中国医学影像学杂志,2006,14(2):91-93.
[24] Cwikla J B,Mikolajczak R,Pawlak D,et al.Initial direct comparison of 99mTc-TOC and 999mTc-TATE in identifying sites of disease in patients with proven GEP NETs.J Nucl Med,2008,49(7):1060-1065.
[25] Gomez M,Ferrando R,Vilar J,et al.99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract.Acta Gastroent eml Latinoam,2010,40(4):332-338.
[26] Jing H,Li F,Chen L,et al.Detection of recurrent pancreatic primitive neuroectodermal tumor by tc-99m hydrazinonicotinyl-tyr3-oetreotide scan.Clin Nucl Med,2011,36(1):54-55.
[27] Sepulveda-Mendez J,de Murphy CA,Pedraza-Lopez M,et al.Specificity and sensitivity of 99mTc-EDDA/HYNIC-Tyr (3)-oc-treotide (99mTc-TOC) for imaging neuroendocfine tumors.Nucl Med Commun,2012,33(1):69-79.
[28] 王峰,王自正,姚薇萱,等.99Tcm-生长抑素受体显像对肺癌的诊断价值.中华结核和呼吸杂志,2005,28(4):218-220.
[29] 王叙馥.放射性核素标记奥曲肽诊断小细胞肺癌的研究进展.国外医学放射医学核医学分册,2003,27(1):11-13.
[30] Nocun A,Chrapko B,Golebiewska R,et al.Evaluation of somato-statin receptors in large cell pulmonary neureendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy.Nucl Med Commun,2011,32(6):522-529.
[31] 何小江,黄劲雄,陈贵兵,等.99mTcTc-奥曲肽显像和X线钼靶诊断乳腺癌.中国医学影像技术,2009(10):1892-1895.
[32] Chen L,Li F,Zhuang H,et al.99mTc-HYNIC-TOC scintigraphy is superior to 131TcI-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.J Nucl Med,2009,50(3):397-400.
[33] Czepczynski R,Kosowicz J,Mikolajczak R,et al.New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma.Pol Arch Med Wewn,2006,116(3):853-860.
[34] Kurtaran A,Scheuba C,Kaserer K,et al.Indium-111-DTPA-D-Phe-l-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.J Nucl Med,1998,39(11):1907-1909.
[35] 赵德善,乔振华,张伟华,等.99Tcm-奥曲肽显像在淋巴瘤诊断中的应用.中华核医学杂志,2007,27(4):224-226.
[36] 吴培仁,何小江,许林,等.99Tcm奥曲肽核素显像诊断结直肠癌的研究.中华肿瘤防治杂志,2010(5):381-383.
[37] Gambini JP,Lopez LJ,Quagliata A,et al.99mTc-HYNIC octreotide in neuroblastoma.Ann Nucl Med,2008,22(9):817-819.
[38] Kukwa W,Andrysiak R,Kukwa A,et al.99mTc-octreotide scintigra-phy and somatostatin receptor subtype expression in juvenile nasop-haryngeal angiofibromas.Head Neck,2011,33(12):1739-1746.
[39] 李眉,戴皓洁,王雪,等.99mTc-奥曲肽SPECT/CT评价甲状腺相关性眼病活动期.中国医学影像技术,2011,27(3):505-509.
[40] Sun H,Jiang XF,Wang S,et al.99mTc-HYNIC-TOC scintigraphy inevaluation of active Graves’ ophthalmopathy (GO).Endocrine,2007,31(3):305-310.
[41] 蔡胜,袁岩,姜玉新,等.瘤原性佝偻病致病肿瘤的影像定位诊断.中国医学影像技术,2006,22(12):1873-1876.
[40] 张化冰,潘慧,李方,等.奥曲肽显像诊断肿瘤性骨软化一例.中华医学杂志,2005,85(33):2375-2376.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):17.
[12]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220.
ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(3):220.